Genmab entered into a definitive agreement to acquire ProfoundBio, Inc. for $1.8 billion in cash. ProfoundBio is a privately-owned clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors.    The transaction expands Genmab’s mid- to late-stage clinical pipeline and strengthens its validated suite of technology platforms. Genmab also gains worldwide rights to Pro...